{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T04:33:40Z","timestamp":1793075620252,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd015930","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000}}],"reference-count":65,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd015930.pub2","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T10:51:51Z","timestamp":1787309511000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Alpha 1 antitrypsin augmentation therapy for alpha 1 antitrypsin deficiency-associated lung disease"],"prefix":"10.1002","volume":"2026","author":[{"given":"Patrick","family":"Glaister","sequence":"additional","affiliation":[{"name":"Library and Knowledge Service; East Lancashire Hospitals NHS Trust; Blackburn UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nichola","family":"Hindle Robinson","sequence":"additional","affiliation":[{"name":"Library and Knowledge Service; East Lancashire Hospitals NHS Trust; Blackburn UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Woods","sequence":"additional","affiliation":[{"name":"Library and Knowledge Service; East Lancashire Hospitals NHS Trust; Blackburn UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Bentham","sequence":"additional","affiliation":[{"name":"Chest Clinic; East Lancashire Hospitals NHS Trust; Blackburn UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juiliana","family":"Hamzah","sequence":"additional","affiliation":[{"name":"Chest Clinic; East Lancashire Hospitals NHS Trust; Blackburn UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain","family":"Crossingham","sequence":"additional","affiliation":[{"name":"Chest Clinic; East Lancashire Hospitals NHS Trust; Blackburn UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"10.1002\/14651858.CD015930.pub2-BIB0001|cit1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global strategy for prevention, diagnosis and management of COPD: 2023 report. GOLD 2022, 2023 https:\/\/goldcopd.org\/wp-content\/uploads\/2023\/03\/GOLD-2023-ver-1.3-17Feb2023_WMV.pdf"},{"key":"10.1002\/14651858.CD015930.pub2-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"100287","DOI":"10.1016\/j.liver.2025.100287","article-title":"Alpha-1 antitrypsin deficiency-associated liver disease: a review focusing on new assessment tools and therapies","volume":"19","author":"Marzi","year":"2025","journal-title":"Journal of Liver Transplantation"},{"issue":"7","key":"10.1002\/14651858.CD015930.pub2-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.arbres.2023.03.016.","article-title":"Estimated worldwide prevalence of the PI* ZZ alpha-1 antitrypsin genotype in subjects with chronic obstructive pulmonary disease","volume":"59","author":"Blanco","year":"2023","journal-title":"Archivos de Bronconeumolog\u00eda"},{"issue":"5","key":"10.1002\/14651858.CD015930.pub2-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"1700610","DOI":"10.1183\/13993003.00610-2017","article-title":"European Respiratory Society statement: diagnosis and treatment of pulmonary disease in alpha-1 antitrypsin deficiency","volume":"50","author":"Miravitlles","year":"2017","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD015930.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3109\/15412555.2012.758698","article-title":"Inhaled alpha 1-antitrypsin: gauging patient interest in a new treatment","volume":"10","author":"Monk","year":"2013","journal-title":"COPD"},{"issue":"10","key":"10.1002\/14651858.CD015930.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1007\/s13346-023-01346-3","article-title":"Nebulizers effectiveness on pulmonary delivery of alpha-1 antitrypsin","volume":"13","author":"Bianchera","year":"2023","journal-title":"Drug Delivery and Translational Research"},{"issue":"9","key":"10.1002\/14651858.CD015930.pub2-BIB0007|cit7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007851.pub3","article-title":"Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease","author":"G\u00f8tzsche","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015930.pub2-BIB0008|cit8","unstructured":"Higgins JP Lasserson T Thomas J Flemyng E Churchill R Methodological expectations of Cochrane intervention reviews. Cochrane: London, Version August 2023 Available from https:\/\/community.cochrane.org\/mecir-manual"},{"key":"10.1002\/14651858.CD015930.pub2-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015930.pub2-BIB0010|cit10","unstructured":"What is a Serious Adverse Event? https:\/\/www.fda.gov\/safety\/reporting-serious-problems-fda\/what-serious-adverse-event"},{"key":"10.1002\/14651858.CD015930.pub2-BIB0011|cit11","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Chapter 4: Searching for and selecting studies (chapter last updated March 2025). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5.1 Cochrane, 2025 Available from https:\/\/cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015930.pub2-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jclinepi.2020.11.003","article-title":"Machine learning reduces workload with minimal risk of missing studies: development and evaluation of an RCT classifier for Cochrane Reviews","volume":"133","author":"Thomas","year":"2021","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD015930.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/jrsm.1287","article-title":"Machine learning for identifying randomized controlled trials: an evaluation and practitioner's guide","volume":"9","author":"Marshall","year":"2018","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD015930.pub2-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jclinepi.2020.08.008","article-title":"Cochrane Centralised Search Service showed high sensitivity identifying randomised controlled trials: a retrospective analysis","volume":"127","author":"Noel-Storr","year":"2020","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015930.pub2-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jclinepi.2021.01.006","article-title":"An evaluation of Cochrane Crowd found that crowdsourcing produced accurate results in identifying randomized trials","volume":"133","author":"Noel-Storr","year":"2021","journal-title":"Journal of Clinical Epidemiology"},{"issue":"7","key":"10.1002\/14651858.CD015930.pub2-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Medicine"},{"key":"10.1002\/14651858.CD015930.pub2-BIB0017|cit17","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2026"},{"key":"10.1002\/14651858.CD015930.pub2-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"10","key":"10.1002\/14651858.CD015930.pub2-BIB0019|cit19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015930","article-title":"Alpha 1 antitrypsin augmentation for alpha 1 antitrypsin deficiency associated lung disease","author":"Glaister","year":"2024","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015930.pub2-BIB0020|cit20","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect (chapter last updated August 2023). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5.1 Cochrane, 2025 Available from https:\/\/cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015930.pub2-BIB0021|cit21","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2024"},{"key":"10.1002\/14651858.CD015930.pub2-BIB0022|cit22","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence (chapter last updated August 2023). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from https:\/\/cochrane.org\/handbook"},{"issue":"1","key":"10.1002\/14651858.CD015930.pub2-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"00537","DOI":"10.1183\/23120541.00537-2024","article-title":"Inhaled alpha-1 antitrypsin (AAT) restores lower respiratory tract protease\u2013antiprotease homoeostasis and reduces inflammation in AAT-deficient individuals: a randomised phase 2 study","volume":"11","author":"Brantly","year":"2025","journal-title":"ERJ Open Research"},{"key":"10.1002\/14651858.CD015930.pub2-BIB0024|cit24","unstructured":"Phase II, safety and efficacy study of kamada-alpha-1-antitrypsin (AAT) for inhalation https:\/\/clinicaltrials.gov\/study\/NCT02001688"},{"issue":"9991","key":"10.1002\/14651858.CD015930.pub2-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/S0140-6736(15)60860-1","article-title":"Intravenous augmentation treatment and lung density in severe \u03b11 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial","volume":"386","author":"Chapman","year":"2015","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015930.pub2-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"A3638","DOI":"10.1164\/ajrccm-conference.2015.191.1_MeetingAbstracts.A3638","article-title":"Effect of A1-PI augmentation therapy on biomarkers of elastin degradation: analysis of samples from the rapid trial","volume":"191","author":"Ma","year":"2015","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"5","key":"10.1002\/14651858.CD015930.pub2-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"1800897","DOI":"10.1183\/13993003.00897-2018","article-title":"Safety of biweekly alpha1-antitrypsin treatment in the RAPID programme","volume":"52","author":"Greulich","year":"2018","journal-title":"European Respiratory Journal"},{"issue":"Supplement 59","key":"10.1002\/14651858.CD015930.pub2-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"PA999","DOI":"10.1183\/13993003.congress-2015.PA999","article-title":"Safety of bi-weekly infusion of a1-pI augmentation therapy in RAPID","volume":"46","author":"Seersholm","year":"2015","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD015930.pub2-BIB0029|cit29","first-page":"A6069","article-title":"Iv alpha1 antitrypsin (A1AT) preserves lung density in homozygous alpha1 antitrypsin deficiency (A1ATD); a randomized, placebo-controlled trial","volume":"187","author":"Chapman","year":"2013","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"Suppl 61","key":"10.1002\/14651858.CD015930.pub2-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"OA3416","DOI":"10.1183\/1393003.congress-2017.OA3416","article-title":"Alpha-1 antitrypsin (A1-PI) treatment slows emphysema progression independent of baseline FEV1","volume":"50","author":"Ficker","year":"2017","journal-title":"European Respiratory Journal"},{"issue":"1","key":"10.1002\/14651858.CD015930.pub2-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S2213-2600(16)30430-1","article-title":"Long-term efficacy and safety of alpha1 proteinase inhibitor treatment for emphysema caused by severe alpha1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE)","volume":"5","author":"McElvaney","year":"2017","journal-title":"Lancet Respiratory Medicine"},{"issue":"2","key":"10.1002\/14651858.CD015930.pub2-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"00457","DOI":"10.1183\/23120541.00457-2022","article-title":"The effect of exacerbations on lung density in alpha1-antitrypsin deficiency","volume":"9","author":"Strange","year":"2023","journal-title":"ERJ Open Research"},{"issue":"Supplement 2","key":"10.1002\/14651858.CD015930.pub2-BIB0033|cit33","first-page":"83","article-title":"Long-term efficacy of a1-pI therapy in RAPID and RAPID extension trials","volume":"22","author":"McElvaney","year":"2017","journal-title":"Respirology"},{"issue":"Supplement 59","key":"10.1002\/14651858.CD015930.pub2-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"OA285","DOI":"10.1183\/13993003.congress-2015.OA285","article-title":"Long-term efficacy of a1-pI therapy in RAPID and RAPID extension trials","volume":"46","author":"McElvaney","year":"2015","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD015930.pub2-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"Supplement 2, 7","DOI":"10.1378\/chest.1993054","article-title":"Baseline patient demographics and lung density decline in the rapid trial","volume":"146","author":"Stocks","year":"2014","journal-title":"Chest"},{"key":"10.1002\/14651858.CD015930.pub2-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"1800897","DOI":"10.1183\/13993003.00897-2018","article-title":"Safety of bi-weekly intravenous therapy with alpha-1 antitrypsin","volume":"52","author":"Burdon","year":"2018","journal-title":"Respirology"},{"key":"10.1002\/14651858.CD015930.pub2-BIB0037|cit37","unstructured":"Zemaira in subjects with emphysema due to alpha1-proteinase inhibitor deficiency https:\/\/clinicaltrials.gov\/study\/NCT00261833"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD015930.pub2-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1183\/1393003.congress-2017.OA3416","article-title":"Alpha-1 antitrypsin treatment slows emphysema progression independent of baseline FEV1","volume":"23","author":"Thompson","year":"2018","journal-title":"Respirology"},{"issue":"5","key":"10.1002\/14651858.CD015930.pub2-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1164\/ajrccm.160.5.9901055","article-title":"A randomized clinical trial of alpha1-antitrypsin augmentation therapy","volume":"160","author":"Dirksen","year":"1999","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"5","key":"10.1002\/14651858.CD015930.pub2-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1080\/02841859709172418","article-title":"Progress of emphysema in severe alpha 1-antitrypsin deficiency as assessed by annual CT","volume":"38","author":"Dirksen","year":"1997","journal-title":"Acta radiologica (Stockholm, Sweden: 1987)"},{"key":"10.1002\/14651858.CD015930.pub2-BIB0041|cit41","first-page":"383S","article-title":"A randomized placebo-controlled trial of alpha1antitrypsin augmentation therapy [abstract]","volume":"12","author":"Dirksen","year":"1998","journal-title":"European Respiratory Journal. Supplement"},{"key":"10.1002\/14651858.CD015930.pub2-BIB0042|cit42","unstructured":"Stage 1 study of ARALAST NP and GLASSIA in a1pI deficiency https:\/\/clinicaltrials.gov\/study\/NCT02722304"},{"issue":"1","key":"10.1002\/14651858.CD015930.pub2-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1465-9921-10-75","article-title":"Exploring the optimum approach to the use of CT densitometry in a randomised placebo-controlled study of augmentation therapy in alpha 1-antitrypsin deficiency","volume":"10","author":"Parr","year":"2009","journal-title":"Respiratory Research"},{"key":"10.1002\/14651858.CD015930.pub2-BIB0044|cit44","unstructured":"Alpha-1-antitrypsin (AAT) to treat emphysema in AAT-deficient patients (EXACTLE) https:\/\/clinicaltrials.gov\/study\/NCT00263887 2005 (first posted 7 December 2005)"},{"issue":"6","key":"10.1002\/14651858.CD015930.pub2-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1183\/09031936.00159408","article-title":"Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency","volume":"33","author":"Dirksen","year":"2009","journal-title":"European Respiratory Journal"},{"issue":"5","key":"10.1002\/14651858.CD015930.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1900673","DOI":"10.1183\/13993003.00673-2019","article-title":"Efficacy and safety of inhaled alpha1-antitrypsin in patients with severe alpha1-antitrypsin deficiency and frequent exacerbations of COPD","volume":"54","author":"Stolk","year":"2019","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD015930.pub2-BIB0047|cit47","unstructured":"A clinical trial looking at the safety and effectiveness of a new drug for inhalation, looking to treat alpha-1 antitrypsin deficient patients with emphysema https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2008-005326-36\/SE"},{"key":"10.1002\/14651858.CD015930.pub2-BIB0048|cit48","unstructured":"International study evaluating the safety and efficacy of inhaled, human, alpha-1 antitrypsin (AAT) in alpha-1 antitrypsin deficient patients with emphysema https:\/\/clinicaltrials.gov\/study\/NCT01217671"},{"issue":"Supplement 2","key":"10.1002\/14651858.CD015930.pub2-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"98S","DOI":"10.1378\/chest.117.5_suppl_2.398s","article-title":"Toward a consensus definition for COPD exacerbations","volume":"117","author":"Rodriguez-Roisin","year":"2000","journal-title":"Chest"},{"issue":"Suppl B","key":"10.1002\/14651858.CD015930.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0954-6111(06)80166-6","article-title":"The St George's Respiratory Questionnaire","volume":"85","author":"Jones","year":"1991","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD015930.pub2-BIB0051|cit51","unstructured":"A controlled study with an active treatment and a placebo to assess the efficacy and safety of weekly intravenous product in subjects with pulmonary emphysema due to alpha-1 antitrypsin deficiency https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-001870-38\/ES https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-001870-38\/ES"},{"issue":"Supplement 57","key":"10.1002\/14651858.CD015930.pub2-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"P3395","DOI":"10.1183\/13993003\/erj.42.Suppl_57.P3395","article-title":"SPARTA: efficacy and safety assessment of two regimens of alpha1-proteinase inhibitor in emphysema due to alpha1-antitrypsin deficiency","volume":"42","author":"Forshag","year":"2014","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD015930.pub2-BIB0053|cit53","unstructured":"Efficacy and safety of alpha1-proteinase inhibitor (human), modified process (alpha-1 mp) in subjects with pulmonary emphysema due to alpha1 antitrypsin deficiency (AATD) (SPARTA) https:\/\/clinicaltrials.gov\/study\/NCT01983241"},{"key":"10.1002\/14651858.CD015930.pub2-BIB0054|cit54","unstructured":"Efficacy and safety of alpha1-proteinase inhibitor (human), modified process (alpha-1 MP) in subjects with pulmonary emphysema due to alpha1 antitrypsin deficiency (AATD) (SPARTA) clinicaltrials.gov\/ct2\/show\/NCT01983241"},{"key":"10.1002\/14651858.CD015930.pub2-BIB0055|cit55","unstructured":"Long term safety of alpha1-proteinase inhibitor in subjects with alpha1 antitrypsin deficiency (SPARTA-OLE) https:\/\/clinicaltrials.gov\/study\/NCT02796937"},{"key":"10.1002\/14651858.CD015930.pub2-BIB0056|cit56","unstructured":"A prospective phase III multi-center, placebo controlled, double blind study to confirm efficacy and safety of Kamada-AAT for Inhalational 80 mg per day in adult patients with congenital alpha-1 antitrypsin deficiency with moderate airflow limitation https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-000602-30\/NL"},{"key":"10.1002\/14651858.CD015930.pub2-BIB0057|cit57","unstructured":"A Prospective Phase III Multi-center, Placebo Controlled, Double Blind Study to Evaluate the Efficacy and Safety of \"Kamada-AAT for Inhalation\" 80 mg Per Day in Adult Patients With Congenital Alpha-1 Antitrypsin Deficiency With Moderate and Severe Airflow https:\/\/clinicaltrials.gov\/study\/NCT04204252 2019 https:\/\/clinicaltrials.gov\/study\/NCT04204252"},{"key":"10.1002\/14651858.CD015930.pub2-BIB0058|cit58","unstructured":"A Prospective, Randomized, Double-Blind, Parallel Group Study to Evaluate the Safety and Efficacy of ARALAST NP 60 mg\/kg and 120 mg\/kg for Alpha-1 Proteinase Inhibitor (A1PI) Augmentation Therapy in Subjects With A1PI Deficiency and Chronic Obstructive Pu https:\/\/clinicaltrials.gov\/study\/NCT04204252 2020 https:\/\/clinicaltrials.gov\/study\/NCT04204252"},{"key":"10.1002\/14651858.CD015930.pub2-BIB0059|cit59","article-title":"A randomized, placebo-controlled, double-blind, exploratory study of the effect of augmentation therapy in patients with severe alpha-1 antitrysin deficiency (AATD) and chronic obstructive pulmonary disease (COPD)","volume":"Unknown volume","author":"Dirksen","year":"2007","journal-title":"Unknown source"},{"key":"10.1002\/14651858.CD015930.pub2-BIB0060|cit60","unstructured":"Alpha 1-proteinase inhibitor for alpha 1-antitrypsin deficiency Medical letter on drugs and therapeutics 1988"},{"issue":"7","key":"10.1002\/14651858.CD015930.pub2-BIB0061|cit61","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007851.pub2","article-title":"Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease","author":"G\u00f8tzsche","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD015930.pub2-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"100","DOI":"10.15326\/jcopdf.6.1.2017.0185","article-title":"Intravenous alpha-1 antitrypsin therapy for alpha-1 antitrypsin deficiency: the current state of the evidence","volume":"6","author":"Brantly","year":"2019","journal-title":"COPD"},{"key":"10.1002\/14651858.CD015930.pub2-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13023-018-0856-9","article-title":"Alpha-1 antitrypsin deficiency: outstanding questions and future directions","volume":"13","author":"Torres-Dur\u00e1n","year":"2018","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"10.1002\/14651858.CD015930.pub2-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"177\u201384","DOI":"10.1080\/15412550902905961","article-title":"Augmentation therapy for \u03b11 antitrypsin deficiency: a meta-analysis","volume":"6","author":"Chapman","year":"2009","journal-title":"COPD: Journal of Chronic Obstructive Pulmonary Disease"},{"issue":"2","key":"10.1002\/14651858.CD015930.pub2-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/24745332.2024.2443178","article-title":"Alpha-1-antitrypsin deficiency targeted testing and augmentation therapy: a Canadian thoracic society meta-analysis and clinical practice guideline","volume":"9","author":"Hernandez","year":"2025","journal-title":"Canadian Journal of Respiratory, Critical Care and Sleep Medicine"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T04:17:01Z","timestamp":1793074621000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD015930.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":65,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd015930.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]}}}